These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33478841)

  • 1. [COVID-19 vaccine and anticoagulation patients at high cardiovascular risk. SEMERGEN recommendations].
    Pallarés-Carratalá V; Polo García J; Martín Rioboo E; Ruíz García A; Serrano-Cumplido A; Barrios V;
    Semergen; 2021; 47(1):1-3. PubMed ID: 33478841
    [No Abstract]   [Full Text] [Related]  

  • 2. The COVID-19 pandemic: lifestyle and cardiovascular risk factors.
    Bhatnagar D
    Curr Opin Lipidol; 2021 Feb; 32(1):71-73. PubMed ID: 33315619
    [No Abstract]   [Full Text] [Related]  

  • 3. Telemedicine in Cardiology for Outpatient Follow-Up of Patients at High Cardiovascular Risk in Response to the COVID-19 Pandemic.
    Moreira HT; Volpe GJ; Rezek UC; Mendonça PC; Teixeira GCA; Santos BMD; Olivieri APG; Chierice AJA; Monteiro HZ; Araújo NM; Maciel BC; Pazin Filho A; Schmidt A
    Arq Bras Cardiol; 2021 Jan; 116(1):153-157. PubMed ID: 33566981
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter to the Editor: Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City.
    Siniorakis E; Arvanitakis S; Katsianis A; Nikolopoulos I
    J Korean Med Sci; 2021 Apr; 36(15):e113. PubMed ID: 33876590
    [No Abstract]   [Full Text] [Related]  

  • 5. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC28. PubMed ID: 33646836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG skin testing for COVID-19 vaccine allergy.
    Stone BD
    J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1765. PubMed ID: 33838847
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Skowronski DM; De Serres G
    N Engl J Med; 2021 Apr; 384(16):1576-1577. PubMed ID: 33596348
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.
    Paranjpe I; Fuster V; Lala A; Russak AJ; Glicksberg BS; Levin MA; Charney AW; Narula J; Fayad ZA; Bagiella E; Zhao S; Nadkarni GN
    J Am Coll Cardiol; 2020 Jul; 76(1):122-124. PubMed ID: 32387623
    [No Abstract]   [Full Text] [Related]  

  • 11. How important is the second dose of the COVID-19 mRNA vaccine?
    Liu AY
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2537. PubMed ID: 34112480
    [No Abstract]   [Full Text] [Related]  

  • 12. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the COVID‑19 pandemic on blood pressure control and cardiovascular risk profile in patients with hypertension.
    Januszewicz A; Wojciechowska W; Prejbisz A; Dobrowolski P; Rajzer M; Kreutz R
    Pol Arch Intern Med; 2021 Oct; 131(10):. PubMed ID: 34704702
    [No Abstract]   [Full Text] [Related]  

  • 14. Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention.
    Volpe M; Battistoni A; ; Bellotti P; Bellone S; Bertolotti M; Biffi A; Consoli A; Corsini A; Desideri G; Ferri C; Modena MG; Nati G; Pirro M; Rubattu S; Tocci G; Trimarco B; Volpe R; de Kreutzenberg SV
    High Blood Press Cardiovasc Prev; 2020 Oct; 27(5):373-377. PubMed ID: 32734561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in environmental noise during COVID-19 pandemic and cardiovascular disease: A mystery for further investigation.
    Antza C; Stabouli S
    J Clin Hypertens (Greenwich); 2020 Oct; 22(10):1947-1948. PubMed ID: 32882108
    [No Abstract]   [Full Text] [Related]  

  • 16. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
    Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A
    Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 with Cardiovascular Disease: Can It Help Predict Prognosis?
    Xiaoliang Yan ; Jing L; Deng Y
    Heart Surg Forum; 2020 Nov; 23(6):E895-E896. PubMed ID: 33253109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heartbeat: an increase in preventable cardiovascular deaths during the COVID-19 pandemic due to avoidance of medical care.
    Otto CM
    Heart; 2021 Jan; 107(2):89-90. PubMed ID: 33443018
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 vaccine development: What lessons can we learn from TB?
    Safar HA; Mustafa AS; McHugh TD
    Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):56. PubMed ID: 33256750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial commentary: COVID-19 as a cardiovascular disease risk factor.
    Oktay AA; Suboc TM; Volgman AS
    Trends Cardiovasc Med; 2022 Nov; 32(8):476-478. PubMed ID: 35850405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.